B2M is a small, non-glycosylated polypeptide (Hofbauer et al., 2021) elevated in ovarian cancer and critical to mediating tumorigenesis, metastasis, and angiogenesis through various signaling pathways (Sun et al., 2016). This evidence concerns the gene B2M and ovarian carcinoma.